   |
 |
 |
 |
 |
 |
|
|||||
Portfolio News Archive 
|
|||||
Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions in Front of 1,000 Cardiologists at JIM 2007 Conference in Rome
Newton, MA, U.S.A. – February 26, 2007 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it transmitted a live satellite feed of a clinical case, which was performed at the Helios Heart Center in Siegburg Germany, to an audience of over 1,000 interventional cardiologists at the Joint Interventional Meeting (JIM 2007) in Rome. The procedure was performed by Charles A. Simonton, III, M.D., FACC, FSCAI, Director of Adult Cardiology Research at Carolinas Heart Institute, in Charlotte, NC. “The Tryton Side-Branch Stent allowed us to treat a difficult bifurcation lesion with a superb angiographic result, through a 6-French guide, without interfering with my selection of a stent for the main vessel. The final appearance of the side branch origin was particularly impressive, I am not sure we could obtain such a result without Tryton,” said Dr. Simonton.
“JIM 2007 provided an important informational venue, enabling 1,000 interventional cardiologists to review first-in-class devices, such as the Tryton Side-Branch Stent, that will eventually provide a new standard of care for problems they encounter every day,” said JIM 2007 Course Director and Co-chair, Professor Eberhard Grube, M.D.
“We were particularly pleased with the Siegburg, Germany case. The audience was not aware that Dr. Simonton had not even seen a Tryton Side-Branch Stent until 30 minutes before performing the procedure. The routine nature of the case highlights how easily a Tryton Strategy can be incorporated into the interventional armamentarium,” said H. Richard Davis, CTO, Tryton Medical, Inc.
Every year, over half a million bifurcation coronary lesions are sub-optimally treated as no commercially available optimized solution exists for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the side branch vulnerable to thrombosis and restenosis. “This technology has the capacity to redefine the treatment of bifurcation lesions and resolve a frequent dilemma of the interventional cardiologist,” said Professor Serruys, Head of the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.
Unlike other stents and techniques used to treat bifurcation lesions, Tryton’s stent is easy-to-deliver as it uses standard equipment and techniques compatible with 5 French guiding catheters. Tryton greatly facilitates patient treatment, as interventional cardiologists who use the Side-Branch Stent will no longer have to worry about the bifurcation as they will know the side-branch will stay open and, as a result, the interventionalist is liberated to focus on the treatment of the main vessel using their preferred choice of standard equipment.
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are designed to definitively treat bifurcation lesions. 540,000 bifurcation coronary lesions are sub-optimally treated every year with a variety of time consuming and technically challenging procedures. No optimized solution is commercially available for treating bifurcation lesions. As a result, cardiologists are forced to use a provisional strategy which avoids the deployment of a second stent – leaving the un-stented side branch vulnerable to thrombosis and restenosis. The ability to definitively treat bifurcation lesions will enable PCI-stenting to become the new standard of care for the treatment of left main coronary artery disease rather than bypass surgery.
Tryton Medical’s Side-Branch Stent™ has all the characteristics of a state-of the art workhorse stent, providing proven stent coverage to bifurcation lesions while eliminating the need for provisional stenting. For more information on Tryton Medical, Inc., contact Joe Romano, Partner, HighGround, Inc. at +1 781-279-1320 x 208, jromano@highgroundinc.com or visit www.TrytonMedical.com